westonsmom
New member
Anyone not get this yet. The CFF just e-mailed it to me. Not Weston's mutation but VERY promising!
Cystic Fibrosis Foundation Announces Positive Early Results for
Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
-- Emerging Data Shows Encouraging Response in CF Patients
--Results Validate Investment in Venture Philanthropy Business Model
Bethesda, MD, March 27, 2008 - The Cystic Fibrosis Foundation announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.
Patients who took the drug for 14 days showed significant improvements in several key indicators of cystic fibrosis, including lung function, nasal potential difference measurements and sweat chloride levels. The findings suggest that VX-770 improves function of what is known as the faulty CFTR protein. This early data is promising and could have important implications for studies of other drugs in development.
This is the first time that any potential therapy has improved the abnormal sweat chloride (salt) levels in a person with CF. Excessive sweat chloride is a key clinical indicator of cystic fibrosis. The "sweat test" is the traditional diagnostic test for CF.
"These early results are an extraordinary endorsement of our hypothesis - that small molecules can correct the basic defect and affect the clinical indicators of cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO of the Foundation. "The emerging data for VX-770 represents the most exciting results we've seen from a Phase 2 trial and increase our confidence that we're on the right track."
The compound VX-770 resulted from a collaboration between the Foundation and Vertex. In 1998, the Foundation approached Aurora Biosciences (acquired by Vertex in 2001) and made an initial investment to use cutting-edge technology - known as high throughput screening - to find compounds to attack the core defect in CF. Since that time, the Foundation has invested $79 million in the project, and the two organizations have closely collaborated to advance VX-770 and a second CF compound, known as VX-809, through research and into development.
"At a time when the model of venture philanthropy was wholly untested, the Cystic Fibrosis Foundation was willing to take a chance that Vertex's CF program would yield meaningful results for people with cystic fibrosis," said Joshua Boger, Ph.D., president and CEO of Vertex Pharmaceuticals. "The project carried significant risk that would have dissuaded many companies and investors from moving forward. Today, however, with the Foundation's financial, scientific and clinical network support, we have been able to bring two novel CF compounds into development and are encouraged by these early results for VX-770."
Overall, the Foundation has invested nearly $300 million in CF drug research with dozens of biotech collaborators nationwide. These collaborations with for-profit companies are part of the Foundation's unique venture philanthropy business model. The model, which is being emulated by other orphan disease organizations, has spawned a drug pipeline of more than 30 therapies in development.
-- more --
National Office
6931 Arlington Road, Bethesda, Maryland 20814
(301) 951-4422 (800) FIGHT CF (800) 344-4823 Fax: (301) 951-8378 Internet: www.cff.org E-mail: info@cff.org
Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770, Page 2.
Part One of the Phase 2a trial of VX-770 studied 20 cystic fibrosis patients over a 14-day period. Part Two of the study is expected to begin in the second quarter of 2008. Additional studies will evaluate the longer-term safety and efficacy of the compound.
Cystic fibrosis is a life-threatening genetic disease that affects about 30,000 people in the United States and 70,000 worldwide. CF is caused by a genetic mutation that results in a malfunctioning (or missing) protein that results in an imbalance of salt and water. This imbalance causes a cascade of mucus plugging, infection and inflammation in the lungs and other organs. The primary cause of death in CF is lung disease.
The predicted median age of survival for people with CF is age 37 - more than double what it was 25 years ago.
About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation funds CF research, has 80 chapter and branch offices throughout the country, and accredits a nationwide network of 115 CF care centers, which provide vital treatments and other CF resources to patients and families.
To advance the search for a cure, CFF has invested nearly $300 million in promising scientific research in the biotechnology industry since 1998. As a result, the Foundation has more than 30 potential therapies in its drug discovery and development pipeline. Virtually every approved CF drug available today was made possible because of Cystic Fibrosis Foundation support. For more information visit www.cff.org.
Contacts:
Laurie Fink, Director, Media Relations: 301-841-2602; lfink@cff.org
Amy DeMaria, Senior Vice President, Communications: 301-907-2598; ademaria@cff.org
Cystic Fibrosis Foundation Announces Positive Early Results for
Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
-- Emerging Data Shows Encouraging Response in CF Patients
--Results Validate Investment in Venture Philanthropy Business Model
Bethesda, MD, March 27, 2008 - The Cystic Fibrosis Foundation announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.
Patients who took the drug for 14 days showed significant improvements in several key indicators of cystic fibrosis, including lung function, nasal potential difference measurements and sweat chloride levels. The findings suggest that VX-770 improves function of what is known as the faulty CFTR protein. This early data is promising and could have important implications for studies of other drugs in development.
This is the first time that any potential therapy has improved the abnormal sweat chloride (salt) levels in a person with CF. Excessive sweat chloride is a key clinical indicator of cystic fibrosis. The "sweat test" is the traditional diagnostic test for CF.
"These early results are an extraordinary endorsement of our hypothesis - that small molecules can correct the basic defect and affect the clinical indicators of cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO of the Foundation. "The emerging data for VX-770 represents the most exciting results we've seen from a Phase 2 trial and increase our confidence that we're on the right track."
The compound VX-770 resulted from a collaboration between the Foundation and Vertex. In 1998, the Foundation approached Aurora Biosciences (acquired by Vertex in 2001) and made an initial investment to use cutting-edge technology - known as high throughput screening - to find compounds to attack the core defect in CF. Since that time, the Foundation has invested $79 million in the project, and the two organizations have closely collaborated to advance VX-770 and a second CF compound, known as VX-809, through research and into development.
"At a time when the model of venture philanthropy was wholly untested, the Cystic Fibrosis Foundation was willing to take a chance that Vertex's CF program would yield meaningful results for people with cystic fibrosis," said Joshua Boger, Ph.D., president and CEO of Vertex Pharmaceuticals. "The project carried significant risk that would have dissuaded many companies and investors from moving forward. Today, however, with the Foundation's financial, scientific and clinical network support, we have been able to bring two novel CF compounds into development and are encouraged by these early results for VX-770."
Overall, the Foundation has invested nearly $300 million in CF drug research with dozens of biotech collaborators nationwide. These collaborations with for-profit companies are part of the Foundation's unique venture philanthropy business model. The model, which is being emulated by other orphan disease organizations, has spawned a drug pipeline of more than 30 therapies in development.
-- more --
National Office
6931 Arlington Road, Bethesda, Maryland 20814
(301) 951-4422 (800) FIGHT CF (800) 344-4823 Fax: (301) 951-8378 Internet: www.cff.org E-mail: info@cff.org
Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770, Page 2.
Part One of the Phase 2a trial of VX-770 studied 20 cystic fibrosis patients over a 14-day period. Part Two of the study is expected to begin in the second quarter of 2008. Additional studies will evaluate the longer-term safety and efficacy of the compound.
Cystic fibrosis is a life-threatening genetic disease that affects about 30,000 people in the United States and 70,000 worldwide. CF is caused by a genetic mutation that results in a malfunctioning (or missing) protein that results in an imbalance of salt and water. This imbalance causes a cascade of mucus plugging, infection and inflammation in the lungs and other organs. The primary cause of death in CF is lung disease.
The predicted median age of survival for people with CF is age 37 - more than double what it was 25 years ago.
About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation funds CF research, has 80 chapter and branch offices throughout the country, and accredits a nationwide network of 115 CF care centers, which provide vital treatments and other CF resources to patients and families.
To advance the search for a cure, CFF has invested nearly $300 million in promising scientific research in the biotechnology industry since 1998. As a result, the Foundation has more than 30 potential therapies in its drug discovery and development pipeline. Virtually every approved CF drug available today was made possible because of Cystic Fibrosis Foundation support. For more information visit www.cff.org.
Contacts:
Laurie Fink, Director, Media Relations: 301-841-2602; lfink@cff.org
Amy DeMaria, Senior Vice President, Communications: 301-907-2598; ademaria@cff.org